Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    European archives of psychiatry and clinical neuroscience 249 (1999), S. S99 
    ISSN: 1433-8491
    Keywords: Key words Atypical neuroleptics ; Novel ; antipsychotics ; Negative symptoms
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The results of controlled studies on the efficacy of novel/atypical neuroleptics in negative symptoms are presented. The data show that these drugs are more favorable in the treatment of negative symptoms in acute schizophrenic patients than the classical neuroleptics such as haloperidol and chlorpromazine. Apparently, the greater efficacy in negative symptoms can only partially be explained by indirect effects via better extrapyramidal tolerability, better effects on productive psychotic symptoms etc., and is to a certain degree due to a direct effect of the atypical neuroleptic on negative symptoms. This view is confirmed by results from one trial studying the efficacy of an atypical neuroleptic in patients suffering from chronic schizophrenia with stable, predominant negative symptoms. Parallel to the evaluation of the novel/atypical neuroleptics in negative symptoms, great progress in the methodology of clinical trials in this field has been made.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1433-8491
    Keywords: Neuroleptics ; Negative symptoms ; Risperidone ; Schizophrenia ; Haloperidol
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients. Regression analyses in the total sample and within treatment groups confirmed a strong relationship between changes in negative symptoms and the other variables studied (R2=0.50−0.51,p〈0.001). Only depressive symptoms did not contribute significantly to these results (p〉0.10). Path analysis showed that the greater mean change (p〈0.05) of negative symptoms with risperidone compared to haloperidol could not be fully explained by correlations with favourable effects on positive and extrapyramidal symptoms. The relationship between shift in extrapyramidal symptoms and shift in negative symptoms failed to reach statistical significance; however, there was a clear tendency in the expected direction in both treatment groups.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...